Open Access · CC BY 4.0
Retraction: Correction: Rubidium chloride targets Jnk/p38-mediated NF-κB activation to attenuate osteoclastogenesis and facilitate osteoblastogenesis
Frontiers in Pharmacology · 11.11.2026 · 17
DOI: 10.3389/fphar.2026.2052162 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Pharmacology, online erschienen am 11.11.2026. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Zitieren
APA
(2026). Retraction: Correction: Rubidium chloride targets Jnk/p38-mediated NF-κB activation to attenuate osteoclastogenesis and facilitate osteoblastogenesis. Frontiers in Pharmacology, 17. https://doi.org/10.3389/fphar.2026.2052162
Vancouver
Retraction: Correction: Rubidium chloride targets Jnk/p38-mediated NF-κB activation to attenuate osteoclastogenesis and facilitate osteoblastogenesis. Frontiers in Pharmacology. 2026;17. doi:10.3389/fphar.2026.2052162
BibTeX
@article{euvimed2026,
title = {Retraction: Correction: Rubidium chloride targets Jnk/p38-mediated NF-κB activation to attenuate osteoclastogenesis and facilitate osteoblastogenesis},
journal = {Frontiers in Pharmacology},
year = {2026},
volume = {17},
doi = {10.3389/fphar.2026.2052162}
}
EUVIMED